Verrica Pharmaceuticals VRCA Institutional Ownership

Ownership Summary

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has 39 institutional investors that have filed 13F reports for the period ending March 2026.

• These investors held 22.4% of outstanding shares in March 2026, down from 49.0% in December 2025.
• They increased total shares held in VRCA by 4.01% quarter over quarter, and investors in Verrica Pharmaceuticals stayed flat from a year ago.
• During the quarter, 16 of these 39 funds increased positions in VRCA, 7 reduced exposure, and 16 held steady.
• In total, institutional investors held 4.78Mn shares in Verrica Pharmaceuticals as of March 2026, up by 184.03K shares quarter on quarter, and with no net change year over year.
• Caligan Partners LP holds the largest position in VRCA at 923.91K shares as of March 31, 2026, or 4.34% of shares outstanding.
• Top purchasers of VRCA stock for the quarter ending March 2026 included CANNELL CAPITAL LLC (685.12K), VANGUARD CAPITAL MANAGEMENT LLC (188.76K), GEODE CAPITAL MANAGEMENT, LLC (71.26K), VANGUARD FIDUCIARY TRUST CO (65.1K), MARSHALL WACE, LLP (55.32K).
• The largest sellers of Verrica Pharmaceuticals for the quarter ending March 2026 were ARMISTICE CAPITAL, LLC (600.74K), Stonepine Capital Management, LLC (253.93K), TWO SIGMA INVESTMENTS, LP (67.56K), JANE STREET GROUP, LLC (52.51K), DAFNA Capital Management LLC (19.74K).
• Business Quant data shows the 10 biggest positions in Verrica Pharmaceuticals as of March 2026 are held by Caligan Partners LP (923.91K), Affinity Asset Advisors, LLC (707.34K), CANNELL CAPITAL LLC (685.12K), ARMISTICE CAPITAL, LLC (518.18K), Velan Capital Investment Management LP (471.56K), BOOTHBAY FUND MANAGEMENT, LLC (280.73K), VANGUARD CAPITAL MANAGEMENT LLC (188.76K), DAFNA Capital Management LLC (153.71K), MARSHALL WACE, LLP (140.5K), GEODE CAPITAL MANAGEMENT, LLC (138.92K).